-
公开(公告)号：US20190078056A1
公开(公告)日：2019-03-14
申请号：US16084401
申请日：2017-03-28
发明人： Tae Uotani , Soichiro Kuwabara
IPC分类号： C12N5/071 , C12N7/00 , C12N5/00 , A61K39/145
摘要： The present invention relates to a cloned MDCK cell showing an expansion factor of 4.5 or more when cultured using a microcarrier and a method of culturing the MDCK cell, a method of growing a virus using the method of culturing the MDCK cell, and a cloned MDCK cell showing an expansion factor of 4.5 or more when cultured using a microcarrier.
-
公开(公告)号：US20150044225A1
公开(公告)日：2015-02-12
申请号：US14505515
申请日：2014-10-03
发明人： Kazuyoshi Ikuta , Ritsuko Koketsu , Yoshinobu Okuno , Mikihiro Yunoki , Shoji Ideno , Masatoshi Oshita , Motoki Kuhara , Masatoshi Momota
IPC分类号： C07K16/10
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/76
摘要： Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.
摘要翻译： 本发明提供对人流感病毒具有中和活性的人抗体。 更具体地，提供了识别人流感A型病毒亚型H3N2或人类流感B型病毒中的高度保守区域并具有针对病毒的中和活性的人抗体。 人抗体是人抗流感病毒抗体，其对人甲型流感病毒亚型H3N2具有中和活性，并与人甲型流感病毒亚型H3N2的血凝素HA1区域结合，或者具有中和活性 人流感B病毒，并且作为编码抗体可变区的DNA的碱基序列，包含SEQ ID NO：5〜12中任一项所述的序列。
-
公开(公告)号：US20210062138A1
公开(公告)日：2021-03-04
申请号：US16963643
申请日：2019-01-17
发明人： Zhenyu PIAO , Yuka KOIZUMI , Hiroshi MIYATAKE
摘要： An object of the present invention is to provide a technique capable of further increasing the absolute detection value and/or the ratio of the detection value to a reference in a pneumococcal antibody sample evaluation test, or a technique capable of evaluating pneumococcal antibody samples against a wider variety of pneumococcal strains.
The object is achieved by a medium for preparing a pneumococcal sample for use in a pneumococcal antibody sample evaluation test, the medium containing a solid medium,-
4.发明申请NOVEL EPITOPE AND MECHANISM OF ANTIGEN-ANTIBODY INTERACTION IN AN INFLUENZA VIRUS 审中-公开流感病毒抗原抗体相互作用的新形象和机制公开(公告)号：US20140086927A1
公开(公告)日：2014-03-27
申请号：US14035495
申请日：2013-09-24
申请人： Fujita Health University , The Research Foundation for Microbial Diseases of Osaka University , Osaka University
发明人： Yoshikazu Kurosawa , Yoshitaka Iba , Nobuko Ohshima , Shigeyuki Yokoyama , Mikako Shirouzu , Yoshifumi Fujii , Tomomi Sumida , Kazuyoshi Ikuta , Shota Nakamura , Norihito Kawashita , Mitsuhiro Nishimura , Akifumi Yamashita , Yoshinobu Okuno , Ritsuko Kubota-Koketsu , Masahiro Okubo
IPC分类号： C07K16/10 , G01N33/569
CPC分类号： C07K16/1018 , C07K2299/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , G01N33/56983 , G01N2333/11 , G16B15/00 , G16C20/50
摘要： Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by low pH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HA1 and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH.
摘要翻译： 抗体（Abs）在防止流行性感冒方面发挥作用。 中和抗体可抑制血细胞凝集素（HA）与细胞受体的结合，或阻止由低pH引起的HA的构象变化。 前者Ab与HA1形成的球形头上唾液酸结合口附近的区域结合，通常表现出狭窄的应变特异性。 后者Ab结合主要由HA2形成的茎区，并显示出广泛的应变特异性。 我们分离出一种广泛中和的Ab针对H3N2病毒。 HA / Ab复合物的X射线分析表明，Ab与球状头部侧面的两个相邻的HA单体形成的谷结合。 Ab通过防止在低pH下诱导的HA的构象变化来显示中和活性。
-
公开(公告)号：US20020146434A1
公开(公告)日：2002-10-10
申请号：US09873233
申请日：2001-06-05
IPC分类号： C07H021/04 , A61K039/12 , A61K039/165 , C12N007/00 , C12N007/01 , C07K005/00 , C07K007/00 , C07K016/00 , C07K017/00 , A61K038/00 , C07K001/00 , C07K014/00
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/51 , A61K2039/525 , A61K2039/53 , C12N2760/18422
摘要： Disclosed is a measles virus mutant antigen, comprising at least one protein antigen selected from the group consisting of (I) a measles virus mutant H protein antigen and (II) a measles virus mutant F protein antigen, the measles virus mutant H protein antigen (I) being at least one member selected from the group consisting of the whole protein and fragmentary peptides identified with the positional amino acid numbers of either SEQ ID NO: 2 or SEQ ID NO: 10; and the measles virus mutant F protein antigen (II) 4 being at least one member selected from the group consisting of the whole protein and fragmentary peptides identified with the positional amino acid numbers of either SEQ ID NO: 18 or SEQ ID NO: 20. Also disclosed is a measles virus mutant gene coding for the measles virus mutant antigen. By the use of the measles virus mutant antigen or the gene coding for the same of the present invention, it has become possible to provide efficiently and economically a live attenuated measles vaccine or gene vaccine which is adapted for an epidemic strain of measles virus, and a diagnostic reagent capable of accurately detecting infections with an epidemic strain of measles virus.
摘要翻译： 公开了一种麻疹病毒突变抗原，其包含选自（I）麻疹病毒突变型H蛋白抗原和（II）麻疹病毒突变F蛋白抗原中的至少一种蛋白质抗原，麻疹病毒突变型H蛋白抗原（ I）是选自由SEQ ID NO：2或SEQ ID NO：10的位置氨基酸编号鉴定的全蛋白和片段肽组成的组中的至少一个; 麻疹病毒突变体F蛋白抗原（II）4是选自由SEQ ID NO：18或SEQ ID NO：20的位置氨基酸编号鉴定的全蛋白和片段肽中的至少一种。 还公开了编码麻疹病毒突变抗原的麻疹病毒突变基因。 通过使用麻疹病毒突变抗原或编码本发明相同的基因，已经有可能高效地和经济地提供适用于麻疹病毒流行株的减毒麻疹疫苗或基因疫苗，以及 能够准确检测麻疹病毒流行病毒感染的诊断试剂。
-
公开(公告)号：US20220081682A1
公开(公告)日：2022-03-17
申请号：US17416342
申请日：2019-12-17
发明人： Daisuke Yokouchi , Akiko Miura , Ryu Okada , Yuzo Yamashita , Yuya Sasaki , Shogo Nishihata
IPC分类号： C12N9/52
摘要： Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.
-
公开(公告)号：US11186618B2
公开(公告)日：2021-11-30
申请号：US16335625
申请日：2017-09-21
发明人： Yasuo Yoshioka
IPC分类号： C07K14/415 , A61K9/00 , C07K14/36 , C07K14/315 , C07K19/00 , A61P37/04 , C07K7/06 , A61K47/50 , A61K39/00 , C12P21/02 , C12N15/09
摘要： The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.
-
公开(公告)号：US09493550B2
公开(公告)日：2016-11-15
申请号：US14505515
申请日：2014-10-03
发明人： Kazuyoshi Ikuta , Ritsuko Koketsu , Yoshinobu Okuno , Mikihiro Yunoki , Shoji Ideno , Masatoshi Oshita , Motoki Kuhara , Masatoshi Momota
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/76
摘要： Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.
-
公开(公告)号：US20210338798A1
公开(公告)日：2021-11-04
申请号：US16316186
申请日：2017-07-11
发明人： Takao Fujimoto , Junji Fujita
IPC分类号： A61K39/145 , C12N7/00
摘要： Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).
-
公开(公告)号：US20210261964A1
公开(公告)日：2021-08-26
申请号：US17260418
申请日：2019-07-18
申请人： THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY , OSAKA UNIVERSITY , TEIKYO UNIVERSITY
发明人： Taiki AOSHI , Shohei KOYAMA , Ryo SUZUKI
IPC分类号： C12N15/117 , A61K9/107 , A61K31/7088 , A61K47/28 , A61K47/24 , A61K47/54 , A61P35/00
摘要： An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.023 秒)
